Form D · Pharmaceuticals
RosVivo Therapeutics, Inc.
Reno, NV · CIK 0001866386
Offering snapshot reported Jun 8, 2021 · SEC filing
- Reported sold
- $5.45M Offering amount: $5.45M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $5.45M Reported outside-investor minimum
- First sale
- May 26, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 8, 2021 | Initial | $5,453,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $164K
- Form D file number
- 021-402098
Source: Form D, filed Jun 8, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sandra M. Poudrier | Executive |
| Seungil Ro | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Applied Research Facility, Room 320 Mailstop 0525 1664 N. Virginia Street
Reno, NV, 89557
Reno, NV, 89557